 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Regarding the previous day's parliamentary audit by the Financial Supervisory Service in Yeouido, Seoul, Daewoong Pharmaceutical Co. said on the 18th, "We believe that Daewoong Pharmaceutical's letter to SK Securities Co. in July was an inevitable choice to prevent damage to small investors."
Earlier in mid-July, Daewoong Pharmaceutical sent SK Securities a certificate of contents with the former CEO as the sender. The main reason is that SK Securities' stock report on its rival Medytox was not used from a balanced perspective. It has been controversial in the market when it was reported that it requested an audit of the analyst (researcher) who wrote the report. It is also on the cutting board of the parliamentary audit.
Daewoong Pharmaceutical has stressed its position in a letter that it has asked securities firms to correct the wrong part, judging that serious infringement of investors' rights occurs. Jeon Seung-ho, CEO of Daewoong Pharmaceutical, who attended as a witness to the parliamentary inspection, said, "There was such a serious error in (the stock firm's report) that I responded to it by proving the contents," adding, "If there is a better way, I will follow it later."
"The measure was taken because it was fulfilling its corporate social responsibility to prevent damage to good investors through active explanation," Daewoong Pharmaceutical said. "Some speculative reports that they tried to prevent the publication of the report through external pressure were not true in the first place," he said. "When the report in question was published in early September, it turned out to be not true."
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
